Skip to main content

Table 5 Effects of different doses of TAC with CYC or MMF on the complete response in SLE patients

From: Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients

TAC/CYC/MMF

Non-CR, n (%)

CR, n (%)

OR

(95% CI)

Adjusted OR

(95% CI)

TAC/CYC

 CYC

258(75.7)

83(24.3)

1.00

1.00

 TAC ≤ 2 mg/d

28(58.3)

20(41.7)

2.22(1.19,4.15)

1.74(0.87,3.48)

 TAC 3 mg/d

20(62.5)

12(37.5)

1.87(0.87,3.98)

1.54(0.67,3.57)

 TAC 4 mg/d

3(42.9)

4(57.1)

4.14(0.91,18.9)

3.02(0.61,14.93)

 TAC ≤ 2 mg/d + CYC

41(65.1)

22(34.9)

1.67(0.94,2.96)

1.62(0.80,3.32)

 TAC 3 mg/d + CYC

19(55.9)

15(44.1)

2.45(1.19,5.05)

2.48(1.06,5.80)

 TAC 4 mg/d + CYC

4(36.4)

7(63.6)

5.44(1.55,19.05)

4.87(1.17,20.17)

  P TAC dose*CYC

  

0.001

0.009

TAC/MMF

 MMF

101(77.7)

29(22.3)

1.00

1.00

 TAC ≤ 2 mg/d

28(58.3)

20(41.7)

2.49(1.23,5.04)

2.74(1.27,5.90)

 TAC 3 mg/d

20(62.5)

12(37.5)

2.09(0.91,4.77)

2.41(0.99,5.85)

 TAC 4 mg/d

3(42.9)

4(57.1)

4.64(0.98,21.94)

4.64(0.94,22.86)

 TAC ≤ 2 mg/d + MMF

32(59.3)

22(40.7)

2.39(1.21,4.74)

2.49(1.10,5.64)

 TAC 3 mg/d + MMF

11(47.8)

12(52.2)

3.8(1.52,9.5)

4.58(1.47,14.27)

 TAC 4 mg/d + MMF

4(28.6)

10(71.4)

8.71(2.54,29.81)

8.86(2.31,33.94)

  P TAC dose*MMF

  

0.012

0.011

  1. The confounding factors in the multivariate regression analysis were sex (female = 1, male = 0), age (continuous), SLE disease period (continuous), comorbidities (yes = 1, no = 0), SLEDAI score (continuous), abnormal urinary protein (yes = 1, no = 0), abnormal serum creatinine (yes = 1, no = 0), renal-protective agents (yes = 1, no = 0), HCQ treatment (yes = 1, no = 0), GCs dose (continuous) and other immunosuppressants (yes = 1, no = 0). The MMF treatment (yes = 1, no = 0) was further adjusted in the TAC/CYC group, and the CYC treatment (yes = 1, no = 0) was adjusted in the TAC/MMF group. PTAC dose*CYC is P for the synergy between different doses of TAC and CYC. PTAC dose*MMF is P for the synergy between different doses of TAC and MMF